Zacks Investment Research lowered shares of Hutchison China MediTech Ltd – (NASDAQ:HCM) from a hold rating to a sell rating in a research report sent to investors on Wednesday.

According to Zacks, “Hutchison China MediTech Limited researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. The Company offers drugs for oncology and autoimmune diseases treatment. Hutchison China MediTech Limited is based in Hong Kong. “

Several other brokerages have also recently weighed in on HCM. Canaccord Genuity reaffirmed a buy rating and issued a $20.00 price target on shares of Hutchison China MediTech Ltd – in a research report on Tuesday, December 6th. Stifel Nicolaus reaffirmed a buy rating and issued a $22.00 price target (up previously from $20.00) on shares of Hutchison China MediTech Ltd – in a research report on Tuesday, March 14th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Hutchison China MediTech Ltd – presently has a consensus rating of Buy and a consensus target price of $19.00.

Hutchison China MediTech Ltd – (NASDAQ:HCM) opened at 19.50 on Wednesday. The stock has a 50 day moving average price of $14.30 and a 200 day moving average price of $13.23. The firm’s market cap is $2.37 billion. Hutchison China MediTech Ltd – has a 52-week low of $9.80 and a 52-week high of $21.77.

Your IP Address:

A number of institutional investors have recently made changes to their positions in HCM. Prudential PLC boosted its position in Hutchison China MediTech Ltd – by 41.0% in the fourth quarter. Prudential PLC now owns 1,842,055 shares of the company’s stock valued at $24,997,000 after buying an additional 535,618 shares in the last quarter. Schroder Investment Management Group boosted its position in Hutchison China MediTech Ltd – by 49.9% in the third quarter. Schroder Investment Management Group now owns 624,543 shares of the company’s stock valued at $7,457,000 after buying an additional 208,006 shares in the last quarter. Baillie Gifford & Co. boosted its position in Hutchison China MediTech Ltd – by 0.5% in the fourth quarter. Baillie Gifford & Co. now owns 153,703 shares of the company’s stock valued at $2,086,000 after buying an additional 777 shares in the last quarter. Finally, Matthews International Capital Management LLC purchased a new position in Hutchison China MediTech Ltd – during the fourth quarter valued at approximately $1,376,000. 3.64% of the stock is currently owned by institutional investors and hedge funds.

About Hutchison China MediTech Ltd –

Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

5 Day Chart for NASDAQ:HCM

Get a free copy of the Zacks research report on Hutchison China MediTech Ltd – (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hutchison China MediTech Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Ltd - and related companies with Analyst Ratings Network's FREE daily email newsletter.